Yes, I do think that NHS may be paving the way for much broader use. Real-world results from IFR cases can absolutely support its use in other cancers.
Notably, on the NHS HCD list, the indication for murcidencel is very broad: “cancer”
Look at other drugs on the list—for many of the oncology drugs, the list specifies which type(s) of cancer.
Market Data 
Markets 
